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ABSTRACT
The Markush patent claim arose as a solution to the challenging problem of describing inventions
that could not be defined any other way than by a list of the members of a group. The original
Markush group, claimed in 1923, listed only three alternatives; in the years since, the populations of
these groups have swelled to totals beyond calculation, as pharmaceutical companies took advantage
of the opportunity to claim multitudes of alternative chemical compounds by systematically iterating
the functional groups at various molecular positions. However, without completing the nowimpossible task of synthesizing and testing each of innumerable chemical compounds for patentable
utility, how can a patent applicant realistically have fulfilled the statutory requirements to obtain a
patent? Is the United States now protecting the mere ability to conceive of possible compounds that
may never be synthesized or tested? As the AIA converts our patent system to a first-to-file
structure, and the numbers of Markush group members threaten to bloat even more in the rush to
preserve priority, we must reconsider and reform the Markush claim before the ability to invent
chemical compounds becomes synonymous with the ability to conceive.
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MILLION-CARD MONTE: REFORMING THE MARKUSH CLAIM POST-AIA TO
SAVE SYNTHETIC CHEMICAL INNOVATION
ADAM SUSSMAN*
INTRODUCTION
“Step right up.” “Three-Card Monte is the name of the game.” “Five dollars to
anyone who can find the Red Queen.”1 Imagine this scenario, but before you bet, the
dealer changes the rules by keeping the cards face up for the entire length of the
game. If that seems deceivingly favorable, it’s because you haven’t heard the catch—
you won’t be selecting the Red Queen from among three cards, but from among one
million cards, all of which randomly change positions. And to make the game even
more interesting, the dealer will not tell you which card you have to select in order to
win. Ready to place your bet?
Chemical and pharmaceutical researchers and manufacturers currently face
similar insurmountable odds under U.S. Patent Law. In the United States, patent
claims “particularly point[] out and distinctly claim[] the subject matter which the
inventor . . . regards as the invention” and define the boundaries of patent
protection.2 Patent claims involving chemical compounds often employ Markush
groups.3 Such claims enable inventors to include several combinations of subject
matter, usually constituent molecules, without defining particular combinations of

* © Adam Sussman 2013. J.D. Candidate, May 2014, The John Marshall Law School. B.A.
Chemistry, University of Pennsylvania, May 2002. Ph.D. Chemistry, University of Illinois, Chicago,
August 2010. United States Registered Patent Agent, Reg. No. 70,506. I would like to specifically
thank my family for all of their love and support. Finally, thank you to the staff of The John
Marshall Review of Intellectual Property Law for their invaluable editorial assistance. Any
mistakes in this article are my own.
1 See DUANE SWIERCZYNSKI, THE COMPLETE IDIOT’S GUIDE TO FRAUDS, SCAMS, AND CONS 96
(2003).

In Great Britain, it’s known as “Find the Lady.” The French call it “Bonneteau.”
Here in the states, it goes by a slightly more rough-and-tumble name: three-card
monte. The rules are simple: There are three cards, slightly arched at the middle
so they’ll be easy to grab. One of those cards is a Queen; the other two are not.
The dealer shows you the Queen, then starts moving the cards around. Your job,
as the player, is to keep your eyes on that Queen no matter what. If you can
guess which is the Queen after the dealer shuffles the cards, you win the pot. The
thing is: no player ever wins.
Id.

35 U.S.C. § 112(b) (2012).
8 DONALD S. CHISUM, CHISUM ON PATENTS § 8.06[2] (2012). (“The Markush doctrine
developed as an exception to the . . . ban on alternative language. With chemical compounds, there
may be no suitable phrase to cover the alternatives. . . . [A] claimant could use [a] . . . coined
subgeneric group in the form of ‘material selected from the group consisting of X, Y, and Z.’”)
(quoting Abbott Labs. v. Bazter Pharm. Prods., Inc., 334 F.3d 1274, 1280 (Fed. Cir. 2003)).
2
3
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the group members.4 While Markush-type claims began as a convenient shorthand
for including various combinations, their use has exploded beyond the Patent Office’s
expectations, not only wreaking havoc on chemical manufacturers facing potential
infringement suits, but also stifling innovation. 5
Part I of this comment will explain the role Markush-type claims play in patent
law, as well as key fundamentals required of every patent application. Part II
proceeds by applying current provisions of the law to a modern chemical Markush
group to illustrate problems created by Markush groups having innumerable
combinations. Part III will review recent attempts to reform Markush-type claims
and suggest a novel approach to limit their breadth in the interest of furthering
scientific innovation.
I. BACKGROUND
This background section provides a brief history of the Markush decision and the
subsequent development of alternative claiming, followed by a simple Markush group
example. Then, several requirements for United States patent applications are
briefly discussed, each of which raises unique practical problems for the analysis of
Markush-type claims, which is demonstrated in the next section.
A. The Origin of Markush-Type Claims
The original, allowed Markush patent claim was a solution built on
compromise.6 In 1923, Eugene Markush filed a patent application with the United
States Patent and Trademark Office (“USPTO”) covering his original, organic
chemical compounds.7 To avoid filing multiple applications on closely related
compounds, each of which may not have individually supported a patent, Markush
4 8 CHISUM, supra note 3, § 8.06[2] (“Markush phrasing . . . is a clear and effective form for
claiming classes of chemical compounds.”).
5 Steve Gardner & Andy Vintner, Stronger Protection for New Drugs, PHARMA, May–June
2010, at 46, 46 (“Markush patterns in some Composition of Matter filings have exploded to the point
where it is effectively impossible to verify the millions of structures presented.”). As early as 1934,
the Commissioner of Patents grew concerned about the growing trend of applicants taking
advantage of the Markush group. Ex parte Dahlen, 1934 Dec. Comm’r Pat. 9, 10.

[T]his [Markush] formula has been taken advantage of by many applicants to
multiply their claims far beyond reasonable bounds. The abuse of the Markush
formula has, in many instances, been carried to such excess as to defeat the very
purpose for which a set of claims is intended. In the mass of verbiage presented
by the claims, the invention is effectively concealed rather than clearly pointed
out. It is quite apparent that proper and sensible restrictions must be imposed on
the use of this unusual form of claim, which is distinctly a child of emergency, and
intended for special relief only.
Id.

Ex parte Markush, 1925 Dec. Comm’r Pat. 126 (1924).
Pyrazolone Dye & Process of Making the Same, U.S. Patent No. 1,506,316 (filed Jan. 9, 1923)
(issued Aug. 26, 1924).
6
7
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attempted to claim in the alternative. 8 The patent Examiner objected to the
alternative claim structure, so Markush substituted the original terminology with
one generic term.9 When the Examiner rejected this term as too broad, Markush
coined the language that has come to characterize the claim format named for him:
“material selected from the group consisting of.” 10 The Commissioner of Patents
eventually allowed this phrase upon petition, with Markush’s original three
alternatives listed as group members. 11 However, the Commissioner’s decision came
with a proviso: Group members were allowed only inasmuch as each could actually
replace the others as the selected material.12
When claims are written in the alternative, such as in Markush-type claims, the
scope and clarity of the claims must be precise and unambiguous. 13 Markush-type
claims are not automatically considered indefinite merely because they include large
numbers of species.14 However, if a Markush group is so vastly populated that one
skilled in the art cannot accurately measure the boundaries of the claimed invention,
an Examiner may reject the claim for indefiniteness. 15
Alternatively, or
additionally,16 an examiner may reject a Markush group under the “improper
8 Markush, 1925 Dec. Comm’r at 127. Markush originally claimed “a diazotized solution of
aniline or its homologues or halogen substitutes.” Id.
9 Id. Markush substituted his original claim language with the simple term “mono-amine.” Id.
10 Id. Markush rewrote the claim phrase as “material selected from the group consisting of
aniline, homologues of aniline and halogen substitutes of aniline.” Id. Homologues of aniline are
defined as “bodies in which one or more atoms of the hydrogen of the benzene-nucleus are replaced
by a corresponding number of atoms of methyl or other radical,” which practically amounts to an
extensive variety of compounds in and of itself. ALFRED HENRY ALLEN, AMINES & AMMONIUM
BASES, HYDRAZINES, BASES FROM TAR, VEGETABLE ALKALOIDS 51 (Kessinger Publishing ed. 2009)
(1892).
11 Markush, 1925 Dec. Comm’r at 128 (“[W]here the validity of the claim is not involved, the
paucity of the language may necessitate a waiver of technical rules of this Office, to the end that an
applicant may properly protect his real invention.”).
12 Id.

If, as the Examiner states, there is nothing to indicate that the chlorine products
of aniline could replace aniline in the reaction described in this application, it may
be that the sub-generic term sought to be used is too broad, just as the term
“mono-amine” was held to be, and that applicant would have to substitute for the
expressed used in the expression “material selected from a group consisting of
aniline and homologues of aniline.”
Id.
13 U.S. PAT. & TRADEMARK OFFICE, U.S. DEP’T OF COMMERCE, MANUAL OF PATENT EXAMINING
PROCEDURE § 2173.05(h)(I) (8th ed. Rev. 9, Aug. 2012) [hereinafter MPEP]; Markush, 1925 Dec.
Comm’r at 127.
14 Supplementary Examination Guidelines for Determining Compliance With 35 U.S.C. 112
and for Treatment of Related Issues in Patent Applications, 76 Fed. Reg. 7162, 7166 (Feb. 9, 2011)
[hereinafter Supplementary Guidelines]; In re Gardner, 427 F.2d 786, 788 (C.C.P.A. 1970).
15 Supplementary Guidelines, supra note 14, at 7166. (“For example, a Markush group that
encompasses a massive number of alternative species may be indefinite under § 112, ¶2 if one
skilled in the art cannot determine the metes and bounds of the claim due to an inability to envision
all of the members of the Markush group.”).
16 In re Harnisch, 631 F.2d 716, 721–22 (C.C.P.A. 1980).
An examiner should maintain a
rejection on the basis of “improper Markush grouping” until the applicant amends the language and
limits the claim to those species sharing a “singular structural similarity and a common use,” or
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Markush grouping” doctrine17 if: “(1) The species of the Markush group do not share
a ‘single structural similarity,’18 or (2) the species do not share a common use.” 19
B. A Simple Example
To illustrate the utility of a simple Markush group, consider a U.S. patent
application having independent claim 1 directed to a chemical compound X-R. Now
consider dependent claim 2 directed to a compound according to claim 1, wherein R is
“selected from the group consisting of A, B, and C.” This single dependent claim
using a Markush group could be rewritten as three dependent claims:
2. A compound according to claim 1, wherein R is compound A.
3. A compound according to claim 1, wherein R is compound B.
4. A compound according to claim 1, wherein R is compound C.
So long as group members A, B, and C “belong to a recognized physical or chemical
class or to an art-related class,”20 the Examiner would likely have allowed the
Markush group.
C. Statutory Requirements Under 112
In the centuries since its inception, the USPTO has adopted strict regulatory
and administrative rules to aid implementation of statutory provisions and to govern
the drafting and examination of U.S. patent claim language. 21 Chief among the

provides a satisfactory showing that the included species already meet this requirement.
Supplementary Guidelines, supra note 14, at 7166. An examiner may have reason to reject a
Markush claim under both § 112(b) and the “improper Markush grouping doctrine.” Id.
17 MPEP, supra note 13, § 803.02. Examiners may not refuse to examine the subject matter
applicants regard as their inventions, unless the claimed invention lacks “unity of invention.” See In
re Weber, 580 F.2d 455, 458 (C.C.P.A. 1978); In re Haas, 580 F.2d 461, 464 (C.C.P.A. 1978).
Compounds in a Markush group generally satisfy the unity of invention standard when they have a
common utility, and possess a structural feature critical to such utility. MPEP, supra note 13,
§ 803.02.
18 Harnisch, 631 F.2d at 723; Supplementary Guidelines, supra note 14, at 7166 (“Members of a
Markush group share a ‘single structural similarity’ when they belong to the same recognized
physical or chemical class or to the same art-recognized class.”).
19 Supplementary Guidelines, supra note 14, at 7166 (“Members of a Markush group share a
common use when they are disclosed in the specification or known in the art to be functionally
equivalent.”).
20 MPEP, supra note 13, § 2173.05(h).
21 See, e.g., 35 U.S.C. § 112 (2012) (setting forth the requirements for patent specifications); 37
C.F.R. § 1.75 (2012) (elaborating upon statutory provisions for specifications and claim forms);
MPEP, supra note 13 (providing Patent Examiners with exhaustive guidelines for evaluating patent
applications).
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statutory requirements is adherence to 35 U.S.C. § 112, which supplies the general
framework for patent claims defining an applicant’s invention.22
According to the first paragraph of 35 U.S.C. § 112:
The specification shall contain a written description of the invention, and of
the manner and process of making and using it, in such full, clear, concise,
and exact terms as to enable any person skilled in the art to which it
pertains, or with which it is most nearly connected, to make and use the
same, and shall set forth the best mode contemplated by the inventor or
joint inventor of carrying out the invention.23
Examination of claim language often turns on analyses of the requirements of
the first paragraph of § 112: “(A) A written description of the invention; (B) The
manner and process of making and using the invention (the enablement
requirement); and (C) The best mode contemplated by the inventor of carrying out
his invention.”24 These requirements guarantee that exclusionary rights of patents
depend on the exchange with the public of information enhancing scientific and
technological development.25
1. The Written Description Requirement
The written description requirement serves several purposes.
First, it
demonstrates that the applicant has indeed invented the claimed subject matter. 26
Second, it “ensures that the inventor had possession of . . . the specific subject matter
later claimed by him or her.”27 Third, the requirement promotes the progress of
science28 by ensuring that patentees adequately describe their inventions to the
public in return for their exclusionary rights. 29
To satisfy the written description requirement, the specification “must describe
the claimed invention in sufficient detail that one skilled in the art can reasonably
conclude that the inventor had possession of the claimed invention.” 30 Possession can
be demonstrated in several different ways, including actually reducing the invention
to practice or offering proof conclusive of actual possession. 31 Conforming to the
requirement is a “fact-based inquiry” dependent upon the subject matter of the
See 35 U.S.C. § 112.
Id. § 112(a).
24 Id. § 2161.
25 Id. § 2162.
26 Id. § 2163(I); In re Barker, 559 F.2d 588, 592 n.4 (C.C.P.A. 1977).
27 MPEP, supra note 13, § 2161(I); In re Herschler, 591 F.2d 693, 700–01 (C.C.P.A. 1979).
28 U.S. CONST. art. I, § 8, cl. 8.
29 MPEP, supra note 13, § 2163(I).
30 Id.; Moba, B.V. v. Diamond Automation, Inc., 325 F.3d 1306, 1319 (Fed. Cir. 2003).
31 MPEP, supra note 13, § 2163(I).
An applicant demonstrates possession by “words,
structures, figures, diagrams, and formulas” that fully delineate the claimed invention. Lockwood v.
Am. Airlines, Inc., 107 F.3d 1565, 1572 (Fed. Cir. 1997). One may establish possession through
proof of actual reduction to practice, by submitting drawings or structural chemical formulas
illustrating that the invention was complete, or by providing distinctive, identifying details
sufficient to prove possession of the invention. Pfaff v. Wells Elecs., Inc., 525 U.S. 55, 68 (1998).
22
23
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invention.32
A chemical compound, for example, must be defined by its
distinguishing characteristics.33
The written description of the claimed subject matter receives a strong
presumption of adequacy upon the filing of a patent application. 34 The Patent
Examiner carries the burden of proving the written description inadequate. 35 The
Manual of Patent Examining Procedure (“MPEP”), an Examiner’s bible, dictates a
three-step methodology for the analysis of descriptive adequacy:36 (1) determine what
each claim covers as a whole;37 (2) ensure that applicant provides support for each
element or step of the claimed invention;38 and (3) conclude whether a skilled artisan
would be informed that applicant possessed the entire claimed invention as of the
application filing date.39

32 MPEP, supra note 13, § 2163(I) (quoting Enzo Biochem, Inc. v. Gen-Probe, Inc., 323 F.3d
956, 969–70 (Fed. Cir. 2002)).
33 Amgen, Inc. v. Chugai Pharm. Co., 927 F.2d 1200, 1206 (Fed. Cir. 1991) (“[I]t is well
established in our law that conception of a chemical compound requires that the inventor be able to
define it so as to distinguish it from other materials, and to describe how to obtain it.”).
34 MPEP, supra note 13, § 2163(I)(A).
35 In re Wertheim, 541 F.2d 257, 263 (C.C.P.A. 1976) (“[T]he PTO has the initial burden of
presenting evidence or reasons why persons skilled in the art would not recognize in the disclosure a
description of the invention defined by the claims.”).
36 MPEP, supra note 13, § 2163(II)(A).
37 Id. § 2163(II)(A)(1). Claim interpretation is fundamental to the examination of applications.
Every claim must be individually evaluated and afforded the “broadest reasonable interpretation”
corresponding with the description. In re Morris, 127 F.3d 1048, 1053–54 (Fed. Cir. 1997). The
examiner must evaluate all limitations within the preamble, transition, and body of the claim, and
the limitations of each must derive satisfactory support from the written description. Lockwood v.
Am. Airlines, Inc., 107 F.3d 1565, 1572 (Fed. Cir. 1997). An examiner may issue a rejection citing
inadequate written description if each claim does not recite appropriate structures, acts, or functions
to define its scope and meaning. MPEP, supra note 13, § 2163(II)(A)(1).
38 MPEP, supra note 13, § 2163(II)(A)(2). If those of ordinary skill in the art would consider an
element of the invention necessary to establish possession, the element may be essential. See
Amgen, Inc. v. Chugai Pharm. Co., Ltd., 927 F.2d 1200, 1206 (Fed. Cir. 1991). The examiner must
compare the scopes of the claim and the description in order to evaluate whether the applicant has
established possession, and must perform this comparison according to the level of skill in the art as
of the application filing date. See Wang Labs. v. Toshiba Corp., 993 F.2d 858, 865 (Fed. Cir. 1993).
The disclosure generally requires less specificity to satisfy written description requirement as the
level of skill in the art increases. See Hybritech, Inc. v. Monoclonal Antibodies, Inc., 802 F.2d 1367,
1379–80 (Fed. Cir. 1986).
39 MPEP, supra note 13, § 2163(II)(A)(3)(a). As long as one of ordinary skill in the art could
conclude that the applicant possessed the claimed invention, any detailed disclosure of
distinguishing characteristics providing evidence of such possession satisfies the written description
requirement. Purdue Pharma L.P. v. Faulding Inc., 230 F.3d 1320, 1323 (Fed. Cir. 2000). Examples
of such disclosures include “complete or partial structure, other physical and/or chemical properties,
functional characteristics when coupled with a known or disclosed correlation between function and
structure, or some combination of such characteristics.” Enzo Biochem, Inc. v. Gen-Probe, Inc., 323
F.3d 956, 964 (Fed. Cir. 2002). Chemical inventions are only adequately described if exactly defined
by name, structure, formula, or specific properties, rather than by a mere, prospective synthetic
plan. See Univ. of Rochester v. G.D. Searle & Co., 358 F.3d 916, 927 (Fed. Cir. 2004).
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2. The Enablement Requirement
Patent applications must also be enabling; that is, they must “enable any person
skilled in the art . . . to make and use the [invention].”40
This requirement
meaningfully informs the interested public of the subject matter of the invention. 41
The standard analysis for compliance with the enablement requirement is whether
the claimed invention can be made without “undue experimentation,” which is
informed by several factors.42 Moreover, the enablement requirement is deemed
satisfied if the specification discloses one method to make and use the claimed
invention that “bears a reasonable correlation to the entire scope of the claim.” 43
The extent of information required to enable an invention decreases as the
“knowledge in the state of the art” and the level of predictability in the field
increase.44 If there is predictability in the art, one skilled in the art should be able to
apply known results in the prior art to the claimed invention, and less information is
required for the patent application to be enabling. 45 Certain subject matter,
including chemical reactions, is inherently and famously unpredictable, and
necessitates a disclosure enabling more than one species.46

35 U.S.C. § 112(a) (2012).
MPEP, supra note 13, § 2164.
42 Id. § 2164.01; In re Wands, 858 F.2d 731, 737 (Fed. Cir. 1988). Undue experimentation
factors:
40
41

[I]nclude, but are not limited to: (A) The breadth of the claims; (B) The nature of
the invention; (C) The state of the prior art; (D) The level of one of ordinary skill;
(E) The level of predictability in the art; (F) The amount of direction provided by
the inventor; (G) The existence of working examples; and (H) The quantity of
experimentation needed to make or use the invention based on the content of the
disclosure.
MPEP, supra note 13, § 2164.01(a).
43 Id. § 2164.01(b); In re Fisher, 427 F.2d 833, 839 (C.C.P.A. 1970).
44 MPEP, supra note 13, § 2164.03; Fisher, 427 F.2d at 839.
45 MPEP, supra note 13, § 2164.03.
46 In re Marzocchi, 439 F.2d 220, 223–24 (C.C.P.A. 1971).
[I]n the field of chemistry generally, there may be times when the well-known
unpredictability of chemical reactions will alone be enough to create a reasonable
doubt as to the accuracy of a particular broad statement put forward as enabling
support for a claim. This will especially be the case where the statement is, on its
face, contrary to generally accepted scientific principles. Most often, additional
factors, such as the teachings in pertinent references, will be available to
substantiate any doubts that the asserted scope of objective enablement is in fact
commensurate with the scope of protection sought and to support any demands
based thereon for proof.
Id. This inherent unpredictability of chemical reactions warrants that a disclosure enables more
than one species. Fisher, 427 F.2d at 839.
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3. The Best Mode Requirement
In addition to describing a claimed invention with sufficient detail and enabling
one skilled in the art to make and use the invention, a patent applicant must also
disclose the best mode of carrying out an invention.47 This requirement guarantees
that applicants will offer full disclosures when attempting to obtain patent protection
by prohibiting the active and knowing concealment of the best embodiments of their
inventions.48
Compliance is evaluated based on a two-pronged analysis: If the inventor
possesses a best mode as of the application filing date, 49 then the written description
must disclose that mode.50
Every applicant must disclose the best mode
contemplated, even if that applicant did not discover that mode.51 Prior to enactment
of the America Invents Act (“AIA”), failure to disclose the best mode was grounds for
invalidating a patent.52 However, the AIA expressly removes non-compliance as
grounds for invalidation.53 Applicants also need not specify which embodiments they
consider to be their best.54
4. The Definiteness Requirement
According to 35 U.S.C. § 112(b), the claims must clearly indicate and specifically
define the boundaries of the subject matter to be protected by the patent grant. 55
This requirement is objective and evaluated based on definiteness, or clarity of the
claim boundaries to one of ordinary skill in the art. 56 The definiteness requirement
35 U.S.C. § 112(a) (2012).
MPEP, supra note 13, § 2165; In re Nelson, 280 F.2d 172, 184 (C.C.P.A. 1960) (“[T]he ‘best
mode’ requirement does not permit an inventor to disclose only what he knows to be his second-best
embodiment, retaining the best for himself.”).
49 MPEP, supra note 13, § 2165; Eli Lilly & Co. v. Barr Labs. Inc., 251 F.3d 955, 963 (Fed. Cir.
2001) (categorizing this analysis as “a subjective inquiry which focuses on the inventor’s state of
mind at the time of filing.”).
50 MPEP, supra note 13, § 2165; Eli Lilly, 251 F.3d at 963 (“This is an objective inquiry,
focusing on the scope of the claimed invention and the level of skill in the art.”).
51 Benger Labs. Ltd. v. R.K. Laros Co., 209 F. Supp. 639, 644 (E.D. Pa. 1962) (“[I]f [the
applicant] knows at the time the application is filed, of a better method to practice the invention and
knows it for the best, it would make no difference whether or not he was the discoverer of that
method.”).
52 See, e.g., Spectra-Physics, Inc. v. Coherent, Inc., 827 F.2d 1524, 1537 (Fed. Cir. 1987)
(holding noncompliance with best mode requirement where inventors of a laser did not disclose a
preferred TiCuSil brazing method, which was not found in the prior art nor common criteria for
literature use of TiCuSil); Dana Corp. v. IPC Ltd. P’ship, 860 F.2d 415, 420 (Fed. Cir. 1988) (finding
violation of the best mode requirement because the inventor failed to disclose a known treatment
that he knew was necessary to successful performance of his invention).
53 Leahy-Smith America Invents Act, Pub. L. No. 112-29, § 15, 125 Stat. 284, 328 (2011).
54 Ernsthausen v. Nakayama, 1 U.S.P.Q.2d 1539, 1549, No. 99,255, 1985 WL 71768 (B.P.A.I.
Sept. 30, 1985) (“[T]hat the disclosure includes the best mode contemplated by applicants is enough
to satisfy the statute.”).
55 MPEP, supra note 13, § 2171.
56 Id. Examination protocols establish not only the novelty and nonobviousness of the claimed
invention over the prior art, but whether the claim language is “precise, clear, correct, and
unambiguous.” Id. § 2171. Examination as to patentability considers only the applicant’s
47
48
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demands analysis in light of the particular application contents, the prior art, and
the interpretations of the claim language that would be made by one skilled in the
art.57
D. The Evolving Markush Group
In the ninety years since the Markush claim was conceived, its prevalence in
chemical and pharmaceutical patents has led to format-specific claim examination
protocols.58
However, whereas Markush limited his claimed group to three
alternative members, modern Markush groups have grown exponentially such that a
single claim can cover countless combinations of compounds. 59
Current
supplementary examination guidelines do not forestall the real, alarming possibility
that Markush claim groups may continue to swell in size. 60 The U.S. has now
adopted a first-inventor-to-file system and largely abandoned the best mode
requirement under the AIA.61 The prospective danger of such a system surrounds
the fate of a yet-undiscovered, potentially important or revolutionary chemical
compound, claimed among the multitudes of combinations in a single Markush
group.62 A future miracle-drug may be the next anonymous “Red Queen” one is
forced to blindly select in a hand of Million-Card Monte. With the statutory
requirements of § 112 in mind, the following section will analyze an allowed
Markush-type claim that calls for serious alarm given current Markush group
doctrine.

understanding of his claimed invention, and an examiner should issue a rejection if this
understanding is not specifically and particularly reflected by the claim language. In re Zletz, 893
F.2d 319, 321 (Fed. Cir. 1989).
57 MPEP, supra note 13, § 2173.02. The examiner must analyze each claim as a whole for
definiteness. See Solomon v. Kimberly-Clark Corp., 216 F.3d 1372, 1379 (Fed. Cir. 2000). Rejection
should result if one of ordinary skill in the art could not discern the boundaries of a claim in
attempting to avoid potential infringement. See Morton Int’l, Inc. v. Cardinal Chem. Co., 5 F.3d
1464, 1470 (Fed. Cir. 1993).
58 MPEP, supra note 13, § 2173.05(h).
59 Quinazoline Derivatives, U.S. Patent No. 5,866,572 col.40 l.27 (filed Feb. 13, 1997) (filed Feb.
13, 1997) (issued Feb. 2, 1999).
60 Gardner & Vinter, supra note 5, at 46.
61 Leahy-Smith America Invents Act, Pub. L. No. 112-29, § 3, 125 Stat. 284, 285–93 (2011)
(adopting a “first inventor to file” patent system); Id. § 15(a), 125 Stat. at 328 (“[F]ailure to disclose
the best mode shall not be a basis on which any claim of a patent may be cancelled or held invalid or
otherwise unenforceable.”).
62 Gardner & Vintner, supra note 5, at 46 (“As early as 1935, the United States Patent and
Trademark Office (USPTO) noted that the misuse of Markush structures was ‘like a fire which had
spread beyond control.’”) (quoting V. I. Richard, Claims Under the Markush Formula, 17 J. PATENT
OFFICE SOC. 179, 190 (1935)).
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II. ANALYSIS
Though it may be a scam, and it may be illegal, Three-Card Monte is a
persisting fact of urban life.63 Similarly, the USPTO has permitted patent applicants
to host legitimate games of Million-Card Monte time and again over the last ninety
years through the use of Markush claims. 64
The analysis that follows highlights the problems inherent in conventional
evaluation of chemical inventions by examining a Markush claim that the USPTO
allowed, but should have rejected. As shown below, this Markush claim fails to meet
any of the statutory or regulatory requirements discussed earlier. Currently
implemented interpretations of these requirements also present serious logistical
problems and implicate profound consequences for the fate of claimed, yet technically
undiscovered chemical inventions.
A. A Not-so Simple Example
The first claim of U.S. Patent No. 5,866,572, “Quinazoline Derivatives,”
exemplifies a Markush group structure by representing a vast array of organic
compounds that share the general framework of compound 1 depicted below.65 Each
63 SWIERCZYNSKI, supra note 1, at 98 (“A veteran tosser can set up shop on a busy Manhattan
street corner and expect to make $200 in his first five minutes.”).
64 See infra note 65 and accompanying text.
65 ‘572 Patent, supra note 59, col.40 l.27.
1. A quinazoline derivative of the formula I

wherein X1 is a direct link;
wherein Q1 is a 5-membered heteroaryl moiety containing one heteroatom
selected from oxygen and sulphur, which heterocyclic moiety is a single ring or is
fused to a benzo ring, and Q1 optionally bears up to 3 substituents selected from
halogeno, hydroxyl, amino, trifluoromethoxy, trifluoromethyl, cyano, nitro,
carboxy, carbamoyl, (1–4C)alkoxycarbonyl, (1–4C)alkyl, (1–4C)alkoxy, (2–
4C)alkenyloxy, (2–4C)alkynyloxy, (1–3C)alklenedioxy, (1–4C)alkylamino, di-[(1–
4C)alkyl]amino, pyrrolidin-1-yl, piperidino, morpholino, piperazin-1-yl, 4-(1–
4C)alkylpiperazin-1-yl, (2–4C)alkanoylamino, N-(1–4C)alkylcarbamoyl, N,N-di[(1–4C)alkyl]carbamoyl, amino-(1–4C)alkyl, (1–4C)alkylamino-(1–4C)alkyl, di-[(1–
4C)alkyl]amino-(1–4C)alkyl, pyrrolidin-1-yl-(1–4C)alkyl, piperidino-(1–4C)alkyl,
morpholino-(1–4C)alkyl, piperazin-1-yl-(1–4C)alkyl, 4-(1–4C)alkylpiperazin-1-yl(1–4C)alkyl, halogeno-(2–4C)alkoxy, hydroxy-(2–4C)alkoxy, (1–4C)alkoxy-(2–
4C)alkoxy,
amino-(2–4C)alkoxy,
(1–4C)alkylamino-(2–4C)alkoxy,
di-[(1–
4C)alkyl]amino-(2–4C)alkoxy,
pyrrolidin-1-yl-(2–4C)alkoxy,
piperidino-(2–
4C)alkoxy,
morpholino-(2–4C)alkoxy,
piperazin-1-yl-(2–4C)alkoxy,
4-(1–
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of the labels Q1, Q2, X1, and R1 represents a different menu of chemical functional
4C)alkylpiperazin-1-yl-(2–4C)alkoxy,
(1–4C)alkylthio-(2–4C)alkoxy,
(1–
4C)alkylsulphinyl-(2–4C)alkoxy, (1–4C)alkylsulphonyl-(2–4C)alkoxy, halogeno-(2–
4C)alkylamino,
hydroxyl-(2–4C)alkylamino,
(1–4C)alkoxy-(2–4C)alkylamino,
amino-(2–4C)alkylamino,
(1–4C)alkylamino-(2–4C)alkylamino,
di-[(1–
4C)alkyl]amino-(2–4C)alkylamino, pyrrolidin-1-yl-(2–4C)alkylamino, piperidino(2–4C)alkylamino,
morpholino-(2–4C)alkylamino,
piperazin-1-yl-(2–
4C)alkylamino, 4-(1–4C)alkylpiperazin-1-yl-(2–4C)alkylamino, N-(1–4C)alkylhalogeno-(2–4C)alkylamino,
N-(1–4C)alkyl-hydroxy-(2–4C)alkylamino,
N-(1–
4C)alkyl-(1–4C)alkoxy-(2–4C)alkylamino,
halogeno-(2–4C)alkanoylamino,
hydroxyl-(2–4C)alkanoylamino,
(1–4C)alkoxy-(2–4C)alkanoylamino,
(3–
4C)alkenoylamino, (3–4C)alkynoylamino, amino-(2–4C)alkanoylamino, (1–
4C)alkylamino-(2–4C)alkanoylamino,
di-[(1–4C)alkyl]amino-(2–
4C)alkanoylamino,
pyrrolidin-1-yl-(2–4C)alkanoylamino,
piperidino-(2–
4C)alkanoylamino,
morpholino-(2–4C)alkanoylamino,
piperazin-1-yl-(2–
4C)alkanoylamino and 4-(1–4C)alkylpiperazin-1-yl-(2–4C)alkanoylamino, and
wherein any of the above-mentioned substituents comprising a CH2 (methylene)
group which is not attached to a halogeno, SO or SO2 group or to a N, O or S atom
optionally bears on said CH2 group a substituent selected from hydroxyl, amino,
(1–4C)alkoxy, (1–4C)alkylamino and di-[(1–4C)alkyl]amino;
wherein m is 1 or 2 and each R1 is independently hydrogen, halogeno,
trifluoromethyl, hydroxy, amino, nitro, cyano, carboxy, carbamoyl, (1–
4C)alkoxycarbamoyl, (1–4C)alkyl, (1–4C)alkoxy, (1–4C)alkylamino, di-[(1–
4C)alkyl]amino, (2–4C)alkanoylamino, N-(1–4C)alkylcarbamoyl or N,N-di-[(1–
4C)alkyl]carbamoyl;
and wherein Q2 is phenyl optionally bearing up to 3 substituents selected from
halogeno, trifluoromethyl, cyano, hydroxyl, amino, nitro, carboxy, carbamoyl, (1–
4C)alkoxycarbonyl, (1–4C)alkyl, (1–4C)alkoxy, (1–4C)alkylamino, di-[(1–
4C)alkyl]amino, (2–4C)alkanoylamino, N-(1-4C)alkylcarbamoyl, and N,N-di-(1–
4C)alkylcarbamoyl, or Q2 is a group of the formula II

wherein X2 is a group of the formula CO, C(R3)2, CH(OR3), C(R3)2-C(R3)2,
C(R3)=C(R3), CC, CH(CN), O, S, SO, SO2, N(R3), CON(R3), SO2N(R3), N(R3)CO,
N(R3)SO2, OC(R3)2, SC(R3)2, C(R3)2O or C(R3)2S wherein each R3 is independently
hydrogen or (1–4C)alkyl, Q3 is phenyl or naphthyl or a 5- or 6-membered
heteroaryl moiety containing up to 3 heteroatoms selected from oxygen, nitrogen
and sulphur, which heteroaryl moiety is a single ring or is fused to a benzo ring,
and wherein said phenyl or naphthyl group or heteroaryl moiety optionally bears
up to 3 substituents selected from halogeno, trifluoromethyl, cyano, hydroxyl,
amino, nitro, carboxy, carbamoyl, (1–4C)alkoxycarbonyl, (1–4C)alkyl, (1–
4C)alkoxy, (1–4C)alkylamino, di-[(1–4C)alkyl]amino, (2–4C)alkanoylamino, N-(1–
4C)alkylcarbamoyl and N,N-di-[(1–4C)alkyl]carbamoyl, n is 1, 2 or 3 and each R4
is independently hydrogen, halogeno, trifluoromethyl, cyano, hydroxyl, amino,
nitro, (1–4C)alkyl, (1–4C)alkoxy, (1–4C)alkylamino, di-[(1–4C)alkyl]amino or (2–
4C)alkanoylamino;
or a pharmaceutically-acceptable salt thereof.
Id.
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groups that may be alternatively selected for attachment to the structure of 1 at the
indicated positions.66

For example, compounds 2 through 5 are very different compounds claimed in
the Markush group under common structure 1.67 Substituting different functional
groups imparts different properties to each compound. 68

The entire range of compounds covered in the Markush group of this single
patent claim exceeds 1024 different permutations69—more than a mole of different
Id.
Id.
68 See Thomas H. Fife, General Acid Catalysis of Acetal, Ketal, and Ortho Ester Hydrolysis, 5
ACCOUNTS CHEMICAL RES. 264, 267 (1972). Acid catalysis of acetals can vary between specific and
general depending on whether structural features reduce the C-O bond cleavage energy. Id. at 265.
Additionally, carboxylic acid strength can be directly correlated to the electronegativity of the substituent. See R. Yamdagni & P. Kebarle, Intrinsic Acidities of Carboxylic Acids from Gas-Phase
Acid Equilibriums, 95 J. AM. CHEMICAL SOC’Y 4050, 4051 (1973). Substitution rates at the carbon
adjacent to a conjugated system are enhanced due to the stabilized transition state. See ANDREW
STREITWEISER, JR., SOLVOLYTIC DISPLACEMENT REACTIONS 13 (McGraw-Hill 1962); Francisco
Carrion & Michael J. S. Dewar, MNDO Study of SN2 Reactions and Related Processes, 106 J. AM.
CHEMICAL SOC’Y 3531, 3538–39 (1984). Substituents on an aromatic compound profoundly
influence its reactivity to electrophilic aromatic substitution. FRANCIS A. CAREY & RICHARD J.
SUNDBERG, ADVANCED ORGANIC CHEMISTRY, PART A: STRUCTURE AND MECHANISMS 557 (4th ed.,
Kluwer Academic/Plenum Publishers 2000).
66
67
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possibilities!70 Even present patent claim examination and restriction practices do
not provide for rejection of this claim; the nature of the chemical Markush group
stymies evaluation by revealing practical fallacies in the tests themselves. 71
B. Describe This!
The breadth of this exemplary Markush group might make one raise an eyebrow
in light of the purposes for the written description requirement. It is extremely
unlikely that the applicant claiming this group has definitively “invented” 72 or “had
possession of the claimed subject matter.”73 The indicated methods of demonstrating
possession for chemical compounds include proof of actual reduction to practice or
definition according to distinguishing characteristics, including descriptions of how to

69 ‘572 Patent, supra note
59, col.40 l.27. Though seemingly incredulous, 1.4562•1024
compounds is actually a conservative estimate. The basic aromatic ring structure of Q1, for example,
can be in five different forms with two different points of attachment to formula I. According to the
claim language, each of these ten aromatic ring structures can optionally be substituted with up to
three different substituents, resulting in 570 possibilities for the basic structure of Q 1.
For example, where the claim recites “(1–4C)alkyl,” the language refers to single-bonded alkyl
groups containing one to four carbons. There are eight possibilities: methyl, ethyl, propyl,
isopropyl, n-butyl, s-butyl, t-butyl, and isobutyl (the additional methylcyclopropyl and cyclobutyl
moieties were not included due to the associated ring strains and inherent impracticality). The
claim language recites that these may be possibilities within a functional group that is optionally
substituted at up to three positions on Q1; at minimum, this means 512 possibilities. When there
are multiple “(1–4C)” groups claimed in a substituent, such as in “di-[(1–4C)alkyl]amino-(2–
4C)alkoxy,” which quotes two independent 1–4C groups each chosen from among the above listed
eight possibilities, and additionally seven possibilities for 2–4C alkyl groups, 448 combinations of
groups exist that can optionally be substituted 570 different ways on Q 1. For that one substituent,
the number grows to at least 255,360 such possibilities.
Similarly, a conservative estimate of Q1 includes 345,573 different substituents that can be
arranged 570 distinct ways, for a total of 196,976,610 possibilities. The R 1 group, which can occupy
either of two, or both of two, positions on I encompasses 187 different possibilities, for a total of
35,343 iterations. The groups X2, R4, and Q3 respectively include conservatively estimated
populations of 441, 4160, and 114,018, resulting in a subtotal of 209,172,878,076 possibilities for Q 2.
The three subtotals for Q1, R1, and Q2, when multiplied together, produce 1.4562•1024.
The overall sum does not take into account the range of heteroaryl moieties represented by Q3
of formula II, because unlike most other functional groups listed, it is unclear which of these
heteroaryl moieties are actually stable enough to exist and provide the claimed utility. Inclusion of
even two or three such moieties could further multiply the combinations exponentially.
Additionally, stereochemistry has not been considered at all; each and every alkyl, alkenyl, and
alkynyl group that includes three- or four-carbon substituents includes the possibility of
stereoisomeric compounds. For example, each sec-butyl group exists in two stereochemical
orientations; having n different sec-butyl groups in one structure results in 2n different
diastereomeric compounds, which must be multiplied into the overall count.
70 See MARTIN S. SILBERBERG, CHEMISTRY: THE MOLECULAR NATURE OF MATTER AND CHANGE
90 (5th ed., McGraw-Hill Higher Education 2009). The mole (abbreviated mol) is the International
System of Units unit for the amount of a substance. One mole represents the amount of a substance
containing the same number of entities as there are atoms in exactly 12 g of carbon-12. One mole (1
mol) contains Avogadro’s number of constituents, or 6.022•1023 entities. Id.
71 Supplementary Guidelines, supra note 14, at 7166.
72 MPEP, supra note 13, § 2163(I); In re Barker, 559 F.2d 588, 592 n.4 (C.C.P.A. 1977).
73 MPEP, supra note 13, § 2161(I); In re Herschler, 591 F.2d 693, 700–01 (C.C.P.A. 1979).
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obtain the compounds.74 It is nearly certain to be impractical for even the most
robust pharmaceutical companies to finance separate syntheses of an excess of 10 24
different compounds, especially as these molecules are presumably suited to the
same use given that they are claimed together. However, for each compound to be
individually obtained with purity, each would indeed require an independent
synthetic strategy from starting materials to the claimed product compound.75
Unfortunately, even the most efficient synthetic strategies proposed on paper often
present unworkable dead-ends in the laboratory, continuously challenging a chemist
to revise the original plan.76
The specification of this particular patent gives general and specific examples of
how these compounds might be synthesized; 77 however, each synthesis must be
tailored to the chemical compound synthesized, and functional groups must be
prudently installed so as not to interfere with subsequent functionalization
reactions.78 Though one of ordinary skill in the art of synthetic organic chemistry
might be able to similarly plan a synthesis on paper, such a chemist would still be
forced to perform the actual route to obtain the compound, selecting from the
suggested varieties of listed reagents by trial-and-error.79 Therefore, a patent claim
74 See, e.g., Pfaff v. Wells Elecs., Inc., 525 U.S. 55, 68 (1998) (demonstrating possession by
actual reduction to practice); Amgen, Inc. v. Chugai Pharm. Co., 927 F.2d 1200, 1206 (Fed. Cir.
1991) (indicating possession by characterizing compounds according to unique characteristics,
including the method of obtaining the compound).
75 Robert Burns Woodward, Synthesis, in PERSPECTIVES IN ORGANIC CHEMISTRY 155, 165
(Alexander R. Todd ed., 1956) (“[W]hile analytical and degradative work must always be primary, it
is often synthesis which provides the simplest, most rigorous, and final proof.”).
76 Robert Robinson, Molecular Structure of Strychnine, Brucine, and Vomicine, in 1 PROGRESS
IN ORGANIC CHEMISTRY 2, 2 (J. W. Cook ed., Academic Press, Inc. 1952) (Sir Robert Robinson
saying of strychnine: “For its molecular size it is the most complex substance known.”). R. B.
Woodward said, “If we can’t make strychnine, we’ll take strychnine!” David Dolphin, Robert Burns
Woodward: Three Score Years and Then?, 10 ALDRICHIMICA ACTA 3, 6 (1977). See generally R. B.
Woodward et al., The Total Synthesis of Strychnine, 19 TETRAHEDRON 247, 247–88 (1963); Larry E.
Overman et al., Asymmetric Total Syntheses of (-)- and (+)-Strychnine and the Wieland-Gumlich
Aldehyde, 117 J. AM. CHEMICAL SOC’Y 5776, 5776–88 (1995); Viresh H. Rawal & Seiji Iwasa, A Short,
Stereocontrolled Synthesis of Strychnine, 59 J. ORGANIC CHEMISTRY 2685, 2685–86 (1994); Martin E.
Kuehne & Feng Xu, The Total Synthesis of (±)-Strychnine, 58 J. ORGANIC CHEMISTRY 7490, 7490–97
(1993); Philip Magnus et al., Synthesis of Strychnine and the Wieland-Gumlich Aldehyde, 115 J. AM.
CHEMICAL SOC’Y 8116, 8116–29 (1993).
77 ‘572 Patent, supra note 59, col.18 l.29 (“Any reducing agent known in the art for promoting
a reductive amination reaction may be employed. A suitable reducing agent is, for example, a
hydride reducing agent, for example an alkali metal aluminum hydride such as lithium aluminum
hydride, or preferably an alkali metal borohydride. . . .”). The patent specification provides specific
procedures for the preparation of forty compounds, sixty-five percent of which contain the named
substituent “3-chloro-4-fluoroanilino”; this indicates that the range of specific, synthesized examples
is miniscule compared to the range of potential substituents claimed. Id.
78 FRANCIS A. CAREY & RICHARD J. SUNDBERG, ADVANCED ORGANIC CHEMISTRY, PART B:
REACTIONS AND SYNTHESIS 845–46 (4th ed., Kluwer Academic/Plenum Publishers 2000).
79 ‘572 Patent, supra note 59, col.15 l.39 (“A suitable catalyst for the reaction includes, for
example, a metal catalyst such as a palladium(0), palladium(II), nickel(0) or nickel(II) catalyst, for
example tetrakis(triphenylphosphine)palladium(0), palladium(II) chloride, palladium(II) bromide,
bis(triphenylphosphine)palladium(II) chloride, tetrakis(triphenylphosphine)nickel(0), nickel(II)
chloride, nickel(II) bromide or bis(triphenylphosphine)nickel(II) chloride.”). Entire books have been
written about transition-metal catalysis, which is characteristically delicate and temperamental;
realistically, catalytic success for a specific reaction is much more complex than choosing one option
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covering an excess of 1024 compounds would extravagantly burden those of ordinary
skill in the art with the task of “undue experimentation” by forcing them to
specifically determine how to obtain each compound, rather than making the
applicant perform this necessary research.
The first element in the analysis of descriptive adequacy involves establishing
what a claim covers.80 Unfortunately, language such as, “a 5- or 6-membered
heteroaryl moiety containing up to 3 heteroatoms selected from oxygen, nitrogen and
sulphur, which heteroaryl moiety is a single ring or is fused to a benzo ring,
and . . . optionally bears up to 3 substituents,”81 covers such a variety of possible
heteroaromatic functional groups that the full extent of these groups was difficult to
fathom or consider in the 1024 calculation.82 If one skilled in the art has initial
difficulty in ascertaining the full scope of a claim, comparing the scope of the claim to
that of the written description becomes technically impossible. 83 Only by individually
synthesizing and analyzing each of these claimed compounds could one hope to
determine their physical and chemical properties,84 the specific relationship between
structure and reactivity for each compound,85 and, ultimately, possession of the
from a list. See generally LOUIS S. HEGEDUS, TRANSITION METALS IN THE SYNTHESIS OF COMPLEX
ORGANIC MOLECULES (2d ed., University Science Books 1999).
80 MPEP, supra note 13, § 2163(II)(A)(1).
81 ‘572 Patent, supra note 59, col.41 l.42.
82 Id. It is unclear exactly how many and which heterocycles containing nitrogen, oxygen, or
sulfur, separately or in combination, would be of sufficient stability to provide the claimed utility.
Prudence warrants actual synthesis and analysis of the properties and reactivities of the claimed
compounds with these substituents.
83 Wang Labs. v. Toshiba Corp., 993 F.2d 858, 865 (Fed. Cir. 1993).
84 FRANCIS A. CAREY & ROBERT M. GUILIANO, ORGANIC CHEMISTRY 26–27 (8th ed., McGrawHill 2011). Though several physical and chemical properties can be estimated by comparison to
other compounds previously synthesized and tested, this is at best an extrapolation. Id. Every
compound has a unique set of properties, including the molecular dipole moment, which results from
the three-dimensional vector sum of all of the individual bond dipole moments. Id. at 28.
Consequently, water (H2O) has a bent shape and two strongly polar hydrogen-oxygen bonds that
aggregate to form strong positive and negative molecular poles as a result of electronegativity
differences, whereas carbon dioxide (CO2) has a linear shape so that the two carbon-oxygen double
bonds cancel. Id. at 27. Water molecules bind together like small magnets such that they are more
difficult to separate and require heat to separate into individual molecules in the gas phase.
SILBERBERG, supra note 70, at 451. By contrast, carbon dioxide molecules are in the gas phase at
room temperature because each is nonpolar and therefore not as heavily attracted to other
molecules. Id. at 399. One can imagine that as molecular complexity increases, structure affects
chemical and physical properties in progressively more subtle and complex ways. Id.
85 Enzo Biochem, Inc. v. Gen-Probe, Inc., 323 F.3d 956, 964 (Fed. Cir. 2002). The ortho-paraand meta-directing influences of aromatic functional groups represent one of the earliest defined
structure-reactivity correlations; certain substituents promote substitution of the aromatic ring at
ortho and para positions, while others deactivate the ring and result in meta substitution. CAREY &
SUNDBERG, supra note 68, at 218. Electron-donating p-amino and p-methoxy group substituents on
an aromatic ring increase the stability of the benzylic cation, whereas electron-withdrawing groups
such as p-cyano and p-nitro groups destabilize the cation; cationic stability determines the reaction
rate of substitution. Robert W. Taft et al., The Relationship Between Substituent-Induced Energy
and Charge Effects in Proton-Transfer Equilibriums, 103 J. AM. CHEMICAL SOC’Y 1344, 1346–47
(1981). For addition of cyanide to aromatic aldehydes, the electronic nature and position of the
aromatic substituent influence the reaction equilibrium. Wei-Mei Ching & Roland G. Kallen,
Mechanism of Carbanion Addition to Carbonyl Compounds, 100 J. AM. CHEMICAL SOC’Y 6119, 6122
(1978). Conformation and substituent orientation can have significant effects on reactivity; while
oxidation of cis-4-t-butylcyclohexanol is faster than that of the trans diastereomer, acetylation of the
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entire claimed invention.86 Because the test for descriptive adequacy scientifically
fails, an Examiner should have issued a rejection; instead, listing suitable possible
reagents and general methods for synthesizing compounds which may never have
been, and which may never be, actually synthesized substitutes for proof of actual
possession by the inventor.
C. Unable to Enable
The pure-science, heuristic aspect of synthetic organic chemistry centers around
the journey from inexpensive, simple starting materials (“A”) toward a complex,
active, desired final product (“Z”).87 A chemist can plan a synthetic route using wellknown chemical reactions to transform A into a series of intermediates (“B”, ”C”, etc.)
along the path to Z.88 Just as in the application of general statutes to specific cases, a
well-established reaction with literature precedent may or may not have previously
been applied to specific starting materials or advanced intermediates.89 However,
even synthetic roadmaps that are based entirely on efficient, precedented reactions

cis diastereomer is faster than that of the trans. Ernest L. Eliel et al., Conformational Analysis. XI.
Configurational Equilibria and Chromic Acid Oxidation Rates of Alkylcyclohexanols. Deformation
Effects, 88 J. AM. CHEMICAL SOC’Y 3327, 3331–32 (1966); Ernest L Eliel & Francis J. Biros,
Conformational Analysis. XII. Acetylation Rates of Substituted Cyclohexanols. The Kinetic Method of
Conformational Analysis, 88 J. AM. CHEMICAL SOC’Y 3334, 3341–42 (1966). The cyclohexanone
carbonyl group experiences an asymmetric environment in its chair conformation; small
nucleophiles prefer axial attack of the carbonyl even though the approach is more sterically
hindered.
Benjamin W. Gung, Diastereofacial Selection in Nucleophilic Additions to
Unsymmetrically Substituted Trigonal Carbons, 52 TETRAHEDRON 5263, 5270 (1996). Steric
hindrance refers to the destabilization resulting from two hydrocarbon chains being too close to one
another, and is the major factor determining relative rates of nucleophilic substitution at
substituted methylene groups. Marvin Charton, Steric Effects. III. Bimolecular Nucleophilic
Substitution, 97 J. AM. CHEMICAL SOC’Y 3694, 3694 (1975). Severe angle strain inherent in
molecules such as cyclopropane leads to rapid ring-opening reactions with electrophiles to relieve
the strain and release energy. Joseph B. Lambert et al., Corner Bromination of Cyclopropane, 106
J. AM. CHEMICAL SOC’Y 792, 793 (1984). Molecular torsional strain results from eclipsing of bonds
on adjacent carbons; cyclohexanone can be reduced by sodium borohydride twenty-three times faster
than cyclopentanone because of the respective favorable and unfavorable changes in torsional strain.
Herbert C. Brown & K. Ichikawa, Chemical Effects of Steric Strains—XIV: The Effect of Ring Size
on the Rate of Reaction of the Cyclanones with Sodium Borohydride, 1 TETRAHEDRON 221, 225
(1957).
86 Purdue Pharma L.P. v. Faulding Inc., 230 F.3d 1320, 1323 (Fed. Cir. 2000).
87 Hong Lin & Samuel J. Danishefsky, Gelsemine:
A Thought-Provoking Target for Total
Synthesis, 42 ANGEWANDTE CHEMIE, INT’L EDITION IN ENG. 36, 37 (2003) (“[S]ynthesis is the
expression of our collective understanding of the underlying science of chemistry. It is not unlikely
that these forays will be of greater consequence than the total syntheses themselves.”).
88 Stephen Hanessian, Target-Driven Organic Synthesis: Reflections on the Past, Prospects for
the Future, in CHEMICAL SYNTHESIS: GNOSIS TO PROGNOSIS 61, 71 (Chryssostomos Chatgilialoglu &
Victor Snieckus eds., Springer 1996) (“Target-driven synthesis implies that the prime objective is to
reach the intended target by the most expedient, practical, and hopefully innovative method.
Achieving such an objective without heavily ‘borrowing’ from already tested synthetic methods may
be a very tall order.”).
89 Lin & Danishefsky, supra note 87, at 45 (employing a common reaction, called a “Claisen
rearrangement,” to provide surprising reactivity en route to the target structure of gelsemine).
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may suffer from unforeseen stereochemical, 90 regiochemical,91 or isolation and
purification92 challenges.
A chemist must always wield the most efficient and practical weapon in his
arsenal—actually performing a proposed synthetic route from A to Z and adapting to
the difficulties of the process along the way. 93 Practically speaking, for one of
ordinary skill in the art of synthetic chemistry, no amount of experimentation is
“undue”94 with respect to synthesizing a novel chemical target molecule, especially as
federal case law has conceded the considerable unpredictability of chemical
reactions.95 The “quantity of experimentation” metric must then directly relate to the
amount of practice needed to actually produce and isolate a synthetic target with
reasonable purity in order to enable one successfully. 96 With such a vast number of
compounds claimed in the Markush group given as an example, each of which bears
its own unique set of functional groups and consequent synthetic challenges, 97 a
specification cannot possibly disclose one representative method to make these
compounds that would correlate to the entire claimed invention.98 Therefore, the
90 CAREY & SUNDBERG, supra note 68, at 97.
Racemization occurs when both possible
enantiomers, the non-superimposable mirror-image stereoisomers of a chiral compound, of a product
are generated from a single reactant compound. Id. A reaction may result in complete or partial
racemization depending on whether it produces a racemic mixture or enantiomeric excess. Id.
Epimerization involves the inversion of one of multiple stereocenters in a stereoisomer. Id.
91 THOMAS H. LOWRY & KATHLEEN SCHUELLER RICHARDSON, MECHANISM AND THEORY IN
ORGANIC CHEMISTRY 135 (3d ed. HarperCollins Publishers 1987) (“The terms regioselective and
regiospecific refer to reactions in which bonds can be made or broken in two or more different
orientations. If one orientation is significantly favored, the reaction is regioselective; if one
orientation occurs to the exclusion of the others, the reaction is regiospecific.”). Rather than use
“regioselective,” the adjectives “high” or “low” can be used as modifiers for “regiospecific.” Alfred
Hassner, Regiospecificity. Useful Terminology in Addition and Elimination Reactions, 33 J. ORGANIC
CHEMISTRY 2684, 2685 (1968).
92 CAREY & SUNDBERG, supra note 78, at 847 (“When a reaction is not completely
stereoselective, the product will contain one or more diastereomers of the desired product. This
requires . . . some manipulation to correct the stereochemistry. Fortunately, diastereomers are
usually separable, but the overall efficiency of the synthesis is decreased with each such
separation.”).
93 Hanessian, supra note 88, at 64.

Target molecules may be related to natural products or they may be totally
“unnatural”, arising from a knowledge of the three dimensional X-ray structure of
an enzyme’s active site for example. Extensive structure-activity data on a series
of compounds in combination with X-ray crystallography, molecular modeling, and
computational techniques may suggest a “lead compound” for synthesis. Indeed,
it is through this type of total synthesis that molecules exhibiting nanomolar
levels of biological activity in vitro and in vivo have been attained. The emphasis
on total synthesis has therefore shifted in part from real natural products such as
those offered by fermentation, etc. to man-made molecules based on biological or
physicochemical parameters.
Id. (citation omitted).
94 MPEP, supra note 13, § 2164.01; In re Wands, 858 F.2d 731, 737 (Fed. Cir. 1988).
95 In re Marzocchi, 439 F.2d 220, 223–24 (C.C.P.A. 1971).
96 MPEP, supra note 13, § 2164.01(a).
97 ‘572 Patent, supra note 59, col. 40 l. 27.
98 MPEP, supra note 13, § 2164.01(b); Fisher, 427 F.2d at 839.
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specification would not meet the enablement requirement without disclosing the
actual method of synthesizing each individual claimed compound.
D. Will the Real “Best Mode” Please Stand Up?
As more cards get added to our initial game of Three-Card Monte, the Red
Queen can more easily hide in plain sight. Similarly, though at least one member of
a Markush group had to have been sufficiently conceived and possessed to allow the
claim, common claim-drafting practice involves listing vast libraries of alternative
potential functional groups. 99 Plausibly, only one or a handful out of endless possible
claimed combinations may have actually been synthesized and tested. 100
Principal to the reactivity and function of any chemical compound is its chemical
structure.101 The structure of a compound influences its characteristic physical
properties and reactivity through the three-dimensional, relative arrangements of
component atoms and molecular electron distributions. 102 Minute differences in the
structures of different compounds can result in profound differences in their physical
properties and reactivities.103
Markush claim-drafting practice, in light of the structure-reactivity relationship,
presents two practical concerns. First, we must grapple with the possibility that the

99 Steve Gardner & Andy Vinter, Beyond Markush—Protecting Activity not Chemical Structure,
INNOVATIONS IN PHARMACEUTICAL TECH. 1 (Sept. 2009), available at http://www.cressetgroup.com/publications/Beyond_Markush.pdf (“[I]t has become routine to have multiple R-groups
each with hundreds of defined substituents, generating millions (or billions) of potential
compounds.”).
100 Gardner & Vinter, supra note 5, at 46.
101 See supra note 85 and accompanying text.
102 CAREY & GIULIANO, supra note 84, at 1024–28.

Stereochemistry is the key to understanding carbohydrate structure, a fact that
was clearly appreciated by the German chemist Emil Fischer. . . . Aldopentoses
have three chirality centers. The eight stereoisomers are divided into a set of four
D-altopentoses and an enantiomeric set of four L-aldopentoses. The aldopentoses
are named ribose, arabinose, xylose, and lyxose. . . . [A]ll of these diastereomers
have the same configuration at C-4 and...this configuration is analogues to that of
(+)-D-glyceraldehyde. Among the aldopentoses, D-ribose is a component of many
biologically important substances, most notably the ribonucleic acids. D-Xylose is
very abundant and is isolated by hydrolysis of the polysaccharides present in
corncobs and the wood of trees. The aldohexoses include some of the most
familiar of the monosaccharides, as well as one of the most abundant organic
compounds on Earth, (+)-D-glucose. With four chirality centers, 16 stereoisomeric
aldohexoses are possible; 8 belong to the D series and 8 to the L series. All are
known, either as naturally occurring substances or as the products of synthesis.
Id.; A. J. KIRBY, STEREOELECTRONIC EFFECTS 1 (Oxford University Press, Inc. 1996) (“A molecule’s
bonding electrons serve not only as its skeleton, but also as a rudimentary nervous
system. . . . [E]very nucleus in a molecule can sense the presence of a strongly electronegative atom
or group, or the approach of another molecule, or the changes in electron density . . . when bonds are
made or broken.”).
103 See supra note 84 and accompanying text.
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“best mode contemplated” is not necessarily the best mode in practice. 104 By
disclosing the best mode, the inventor highlights a particular embodiment to those of
ordinary skill in the art as that best suited to practicing the claimed utility.105 If the
inventor legitimately expects others to innovate from the claimed invention,
professional responsibility accompanies such a proclamation. No one, including the
inventor or examiner, can responsibly contemplate which of the multitudes of
compounds constitutes the best mode—short of synthesizing and testing the
properties and reactivity of each and every different compound. 106 Without having
performed scientific analyses on each claimed compound, only a small likelihood
exists that the inventor has actually even discovered the true best mode among all of
the available alternatives. Thus, disclosing the best mode reduces to irresponsible,
uninformed guessing. Consequently, knowing whether the inventor possessed a best
mode107 to begin with becomes a murky and challenging determination, and the test
for compliance with the best mode requirement fails. 108
The second concern stems from the exhaustive listing of alternative, substituent
functional groups commonly practiced in drafting Markush claims. In claiming such
a vast number of alternatives, the drafting process could result in the claiming of a
compound that, if actually synthesized and tested, might ultimately prove to be
better than the contemplated best mode. Even if not a better compound for the
claimed utility, such a claimed alternative compound could have a unique, novel, and
miraculous reactivity; however, as a mere alternative, the compound, though
claimed, might never be synthesized, tested, or discovered.
E. Definitely Maybe
It’s quite probable that as Three-Card Monte bloats into Million-Card Monte you
would begin to feel utterly defeated by trying to keep track of the Red Queen.
Though a Markush group may encapsulate more than 10 24 compounds and
nevertheless clearly define its boundaries, 109 even one of ordinary skill in the art
could reasonably lose track of the boundaries of such a claim. 110
In fact,
Supplementary Examination Guidelines cite such failure to envision all the members
of a Markush group as grounds for potentially rejecting the claim. 111 Certainly,
however, the benchmark for such a rejection based on indefiniteness need not be the
MPEP, supra note 13, § 2165; In re Nelson, 280 F.2d 172, 184 (C.C.P.A. 1960).
MPEP, supra note 13, § 2165; Eli Lilly & Co. v. Barr Labs. Inc., 251 F.3d 955, 963 (Fed. Cir.
2001) (“[T]he public receives knowledge of the preferred embodiments for practicing the claimed
invention.”).
106 MPEP, supra note 13, § 2165.03 (“The examiner should assume that the best mode is
disclosed in the application, unless evidence is presented that is inconsistent with that
assumption. . . . The information that is necessary to form the basis for a rejection based on the
failure to set forth the best mode is rarely accessible to the examiner . . .”); see supra note 85 and
accompanying text.
107 MPEP, supra note 13, § 2165; Eli Lilly & Co. v. Barr Labs. Inc., 251 F.3d 955, 963 (Fed. Cir.
2001).
108 MPEP, supra note 13, § 2165.
109 Id. § 2171.
110 See Morton Int’l, Inc. v. Cardinal Chem. Co., 5 F.3d 1464, 1470 (Fed. Cir. 1993).
111 Supplementary Guidelines, supra note 14, at 7166.
104
105
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point at which confusion arises or the power to envision all possible group members
fails; Markush groups can serve their purpose to claim in the alternative without
being so large as to trigger such analyses. 112
Current supplementary guidelines reveal additional problems with respect to
effectively rejecting Markush groups under the “improper Markush grouping”
doctrine or restricting them.113 Though all group members may share a “single
structural similarity,”114 problems arise with determining whether all group
members share a common use.115 Short of synthesizing and testing each group
member, the properties imparted to the members by the various functional groups
raise doubts as to common utility.
F. So What’s The Big Deal?
A hypothetical example best illustrates the danger of broad Markush claiming.
Suppose sixty-five years ago, a pharmaceutical company conducted promising
chemotherapeutic clinical trials and found a structural pattern among a handful of
effective compounds. In an effort to protect its research, the company broadly
claimed in the alternative every conceivable structural variation, inadvertently
included in which were the anthracyclines.116 Though unknown at the time and far
afield of the company’s focus or interest, the anthracyclines that were claimed
included doxorubicin (“DXR”), commonly used today in chemotherapy to effectively
treat a variety of cancers.117 When other researchers later discovered and tested
112 N,N-Diacylpiperazine Tachykinin Antagonists, U.S. Patent No. 5,344,830 col.59 l.34 (filed
Dec. 10, 1992) (issued Sep. 6, 1994) (including as the first claim: “A compound which is selected
from the group consisting of: 1) 4-(N,N-di-n-pentylcarbamoyl)-1-(N,N-diphenyl-carbamoyl)-N-[3-(4morpholinyl)propyl]-2-piperazinecarboxamide; 2) 4-(N,N-di-n-pentylcarbamoyl)-1-(N,N-diphenylcarbamoyl)-N-[2-(4-morpholinyl)ethyl]-2-piperazinecarboxamide; 3) 4-(N,N-di-n-pentylcarbamoyl)-1(N,N-diphenyl-carbamoyl)-N-[2-(1-piperidinyl)ethyl]-2-piperazinecarboxamide;
4)
4-(N,N-di-npentylcarbamoyl-1-(N,N-diphenyl-carbamoyl)-N-[2-(acetamido)ethyl]-2piperazinecarboxamide; . . . 22) (S)-4-(N,N-di-n-pentylcarbamoyl)-2-(2-N-(benzyloxycarbonylmethyl)N-methylamino)ethylaminocarbonyl)piperazine; or a pharmaceutically acceptable salt thereof.”).
The total number of compounds claimed in this Markush group was twenty-two. Id.
113 See In re Harnisch, 631 F.2d 716, 721–22 (C.C.P.A. 1980) (rejecting claims under “improper
Markush grouping” doctrine); MPEP, supra note 13, § 803.02 (delineating Markush group
restriction practices).
114 Harnisch, 631 F.2d at 723; Supplementary Guidelines, supra note 14, at 7166.
115 Supplementary Guidelines, supra note 14, at 7166.
116 A. Fujiwara et al. Anthracycline Antibiotics, 3 CRITICAL REVS. IN BIOTECHNOLOGY 133, 133
(1985). The anthracyclines include several of the most effective anticancer treatments ever
discovered, and have demonstrated results against more types of cancer than any other known
category of chemotherapeutic compounds. R.B. Weiss, The anthracyclines: will we ever find a better
doxorubicin? 19 SEMINARS IN ONCOLOGY 670, 671 (1992).
117 Doxorubicin
(Systemic),
MAYOCLINIC.COM,
http://www.mayoclinic.com/health/druginformation/DR202209 (archived at Internet Archive: Wayback Machine Apr. 3, 2007). Doxorubicin
is a common chemotherapy treatment for leukemia, Hodgkin’s lymphoma, and cancers of the
bladder, breast, stomach, lung, ovaries, thyroid, and other tissues. Id. When ovarian cancer has
progressed or recurred after other forms of chemotherapy, oncologists prescribe Doxil, the
encapsulated form of doxorubicin. Doxil Product Information Booklet, ORTHO BIOTECH PRODUCTS,
L.P. 1, 2 (2007), http://www.orthobiotech.com/common/prescribing_information/DOXIL/PDF/DOXIL_
PI_Booklet.pdf (archived at Internet Archive: Wayback Machine Sep. 21, 2007). In 2011 alone,
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DXR, determined its efficacy in treating cancers, elucidated its structure, and filed a
patent application, the USPTO Examiner would have rejected their claims, citing the
earlier Markush claim. How much further effort, time, or resources could these
researchers or their benefactors then justify in studying chemical compounds given
that all closely related analogues had already been protected? In abandoning their
research as unprofitable, these scientists would potentially sacrifice the use of DXR
to effectively treat cancer patients worldwide over the last forty years. 118
III. PROPOSAL
The game of Million-Card Monte guarantees that the player loses his money
when he bets. Though odds weigh heavily against completely eradicating this
swindle, modifying the rules could reduce the player’s odds of losing.
This proposal highlights a recent, legislative attempt to control the expanding
sizes of Markush groups. Though initially unsuccessful, and inherently problematic,
the USPTO did subsequently adopt guidelines to curtail broad Markush claiming.
The real solution to the problem ultimately could stem from one of several attractive
alternatives.
A. One Pebble In A River
In August 2007, the USPTO proposed changes to its treatment of claims
containing alternative language, including Markush claims. 119 The USPTO grew
concerned about the time that it was taking for examiners to analyze Markush group
alternatives and attempted to shift the burden of proving the “relatedness” of
alternatives back to the applicant.120
The proposed rules limited each claim to a single invention. For subject matter
reading on multiple species with alternative language, a single invention occurs
when all species share a substantial feature required for common utility, or all

worldwide sales of doxorubicin and its various encapsulated forms reached approximately $20
billion. Product Sales (Actuals) for Doxorubicin, MEDTRACK.COM, http://v1.medtrack.com/disease
hubs/dhpagetwo.asp?c2=searchbyproduct&c3=3&c1=doxorubicin&view=ProductSales%20View&
(last visited Dec. 27, 2012).
118 F. Arcamone et al., Adriamycin, 14-hydroxydaunomycin, a new antitumor antibiotic from S.
peucetius var. caesius, 11 BIOTECHNOLOGY & BIOENGINEERING 1101, 1101 (1969).
119 Examination of Patent Applications That Include Claims Containing Alternative Language,
72 Fed. Reg. 44,992, 44,995 (Aug. 10, 2007) [hereinafter Proposed Rules].
120 Application of Weber, 580 F.2d 455, 458 (C.C.P.A. 1978) (“The struggle to balance the needs
of inventors . . . with those of the Office for search and examination responsibilities
commensurate . . . with resources is a long-standing one. The Office ‘must have some means for
controlling . . . examiners’ caseloads and the . . . searching done per filing fee.’”). The USPTO
expected that more drastic measures were required to ameliorate examination difficulties incurred
by the use of Markush groups than by simply monitoring the extent of searching per filing fee.
Proposed Rules, supra note 119, at 44,994. According to the USPTO, more thorough and more
reliable examination would stem from demanding that applicants using alternative language
maintain relatedness among the claimed alternatives. Id. at 44,992.
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species are obvious over one another.121 The changes required that the number and
presentation of alternatives not detract from comprehension of the claim language,
and that each alternative in a list be substitutable for each other.122 Finally, the
rules eliminated overlapping of alternatives, which creates difficulty in concluding
whether a claim contains more than one invention.123
The USPTO subsequently solicited comments from the public on the proposed
changes.124
The comments, received from intellectual property organizations,
corporations, associations, law firms, and individuals, recognized the cited problems
but generally criticized the approach taken by the proposed rules. 125 Eventually, the
121 Proposed Rules, supra note 119, at 44,996 (“The [substantial] feature could be a common
structure, material, or act necessary for at least one shared specific, substantial, and credible
utility. . . . The second definition codifies the long-standing principle that it is improper to restrict
between species that are prima facie obvious over each other.”).
122 Id.
This suggestion stems from the assertion in In re Driscoll. 562 F.2d 1245, 1249
(C.C.P.A. 1977) (“[M]embers of [a] Markush group are . . . alternatively usable for the purposes of
the invention.”).
123 Id. Alternatives may fully overlap, for example, in a claim stating “selected from the group
consisting of an adhesive agent, tape, and glue,” or partially overlap, such as “selected from the
group consisting of citrus fruits and tropical fruits.” Id. at 44,997. The rules proposed that
applicants file multiple claims ranging in scope from the broadest to which they believed they are
entitled to the narrowest that they are willing to take, which would eliminate the practice of
appearing to narrow claim scope by “nest[ing] sets of overlapping alternatives.” Id.
124 Examination of Patent Applications That Include Claims Containing Alternative Language,
73 Fed. Reg. 12,679, 12,680 (Mar. 10, 2008) [hereinafter Request for Comments].
125 Comments on August 2007 Examination of Patent Applications That Include Claims
Containing Alternative Language, USPTO.GOV, http://www.uspto.gov/ip/rules/comments/markush
.jsp (last modified July 4, 2009). The American Intellectual Property Law Association (“AIPLA”)
believed that “the proposed rules place too much authority in the hands of patent examiners to
determine the subject matter that applicants regard as their invention. . . .[T]he proposed rules
place artificial limits on those who use alternatives to define . . . their invention.” Letter from Am.
Intellectual Prop. Law Ass’n to The Honorable Jon Dudas, U.S. Patent & Trademark Office, Comm’r
for Patents, Comments on Proposed Rules related to “Examination of Patent Applications That
Include Claims Containing Alternative Language” (Oct. 15, 2007), http://www.uspto.gov/web/offices/
pac/dapp/opla/comments/markush/aipla.pdf. Similarly, the Intellectual Property Owners Association
(“IPO”) suggested that the USPTO proposal “unduly limit the protection sought by applicants. . . .
[S]trict adherence to the letter of some of the proposed rules would necessarily result in a greater
number of restriction of inventions, which would undermine the purpose of the rules,” to ameliorate
the workload on the examiners. Letter from Intellectual Prop. Owners Ass’n to The Honorable Jon
Dudas, U.S. Patent & Trademark Office, Comm’r for Patents, Comments on Proposed Rules related
to “Examination of Patent Applications That Include Claims Containing Alternative Language”
(Oct. 15, 2007), http://www.uspto.gov/web/offices/pac/dapp/opla/comments/markush/ipo.pdf. Eli Lilly
and Company (“Lilly”) went as far as to propose a system of fees corresponding to the amount of
work with which applicants burden examiners. Letter from Eli Lilly Co. to The Honorable Jon
Dudas, U.S. Patent & Trademark Office, Comm’r for Patents, Comments on Proposed Rules related
to “Examination of Patent Applications That Include Claims Containing Alternative Language”
(Oct. 8, 2007), http://www.uspto.gov/web/offices/pac/dapp/opla/comments/markush/lilly.pdf.

Fee-based differentiation of this type is a preferable and fairer means for assuring
that inventors whose inventions may be best protected through extensive use of
alternative claiming practices can do so—provided that they pay their own way
through the patent examining process. If alternative claiming practices mean that
a single claim in a single patent application entails the equivalent workload for a
patent examiner of examining 10, 100, or more typical patent applications, then
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USPTO adopted Supplementary Examination Guidelines in 2011 containing similar
provisions to assist Office personnel with examination of claims for compliance with
35 U.S.C. § 112.126
B. Alternative Alternatives
As illustrated in the Analysis, attempts to evaluate Markush claim language,
even under the Supplementary Guidelines, raised practical problems where some of
the alternative claimed chemical compounds had never been synthesized or tested
and a “common use” of such alternatives could only be constructively determined. 127
Therefore, the possibility of an undiscovered but claimed miracle compound that does
not actually have the requisite “common use” remains. The proposed rules and
adopted guidelines endeavored to reduce the sizes of Markush groups in order to ease
the work performed by examiners, rather than concentrating on the consequences
that Markush claims posed for innovation and claimed but unknown alternatives.
1. The Sledgehammer Approach
Typically, only a hardline approach avoids the slack that has led to the slippery
slope of Markush group claiming over the last century. The simplest and most
logical approach to the problem would be to eliminate the Markush claim completely.
At first blush this approach may appear harsh and superfluous. Certainly,
examples have illustrated the possibility of claiming in the alternative at a level at
which one of ordinary skill could reasonably presume that every Markush group
member had been reduced to practice or otherwise possessed, and evaluated the
claimed utility.128 Therefore, no need should exist for claiming more than those
alternatives for which an applicant has demonstrated possession and the claimed
utility. Markush groups remain unique aberrations, tolerated by the USPTO despite
the fact that applicants claim subject matter extending far beyond what their patent
applications indicate they have possessed. Applicants should not be allowed broad
claims for multitudes of chemical compounds beyond that which they have actually
discovered simply by claiming in the alternative.
2. Hit Them Where It Hurts
Short of completely abandoning the Markush claim, another appealing option
incentivizes smaller, more refined Markush groups while simultaneously rewarding
the fees for examination should reflect the magnitude of the differential
examination work being requested by the inventor.
Id. (emphasis in original).
126 Supplementary Guidelines, supra note 14, at 7162.
127 See supra Part II.E.
128 ‘316 Patent, supra note 7, at col.4 l.31; ‘830 Patent, supra note 112, at col.59 l.34.
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the USPTO. Currently, applicants pay a flat fee for filing, search, and examination
of a standard application encompassing a set number of patent claims, with
surcharges added for each additional claim. 129 Therefore, the applicant has a vested
interest in claiming as many alternatives as possible in the claims that were initially
purchased.
Markush groups would immediately and dramatically shrink in size if the
USPTO adopted a system in which applicants paid a surcharge for each Markush
group member. Applicants would negotiate balances between the desires to claim as
broadly as possible in the alternative and to maintain minimal expense. The
USPTO, a fee-based government office that raises funds primarily by charging patent
applicants, would regularly enjoy the influx of revenue resulting from a pay-pergroup-member system.130 Certainly, such a Markush surcharge system would
require careful calibration to ensure that applicants would rather pay group-member
surcharges than the fee for adding additional claims.
3. Applicant Guidance Suggested
If abandoning Markush claiming or changing the pay structure for these claims
seem impractical, a third alternative would supplement current descriptive
requirements. An applicant wishing to continue to claim multitudes of alternatives
in Markush groups without paying any more than others who claim single inventions
should at least make a greater attempt to distinguish between alternatives that are
better suited to the claimed utility of their inventions.
Even if many of the claimed chemical alternatives have never been synthesized
or tested, an applicant has resources at his disposable to make predictions based on
current scientific evidence as to which alternatives are more or less likely to possess
the claimed utility.131 The burden of such predictive analysis should fall upon the

129 MPEP, supra note 13, § 607 (“37 CFR 1.16(h) sets forth the excess claims fee for each
independent claim in excess of three. 37 CFR 1.16(i) sets forth the excess claims fee for each claim
(whether independent or dependent) in excess of twenty.”).
130 Omnibus Reconciliation Act of 1990, Pub. L. No. 101-508, § 10101, 104 Stat. 1388, 1388–91
(1990) (instituting direct funding for the USPTO from user fees). The USPTO budget is allocated
based on the projected revenue it collects in user fees. Id. § 10101, 104 Stat. at 1388–91; see also
Stuart Minor Benjamin & Arti K. Rai, Who’s Afraid of the APA? What the Patent System Can Learn
from Administrative Law, 95 GEO. L. J. 269, 314 (2007) (“[USPTO] is favorably disposed to patent
holders . . . [in part because] the agency as a whole is funded by applicant fees.”); Jeanne C. Fromer,
Patent Disclosure, 94 IOWA L. REV. 539, 579 n.178 (2009) (“A pro-patent bias also arises because the
PTO is wholly funded by patent-applicant fees.”); Clarisa Long, The PTO and the Market for
Influence in Patent Law, 157 U. PA. L. REV. 1965, 1994 (2009) (“[T]he PTO’s budgetary structure
creates a bias in favor of granting patents and encouraging inventors to apply for patents. It also
crates the incentive for the PTO to favor patentees (who pay fees to the PTO) over nonpatentees
(who do not).”); Michael J. Meurer, Patent Examination Priorities, 51 WM. & MARY L. REV. 675, 699
(2009) (“The PTO has endorsed a ‘customer service orientation that stresses the importance of
meeting the needs of patent applicants. This orientation may be motivated in part by the
dependence of the [A]gency on fees to fund its operation.”).
131 ERNEST L. ELIEL & SAMUEL H. WILEN, STEREOCHEMISTRY OF ORGANIC COMPOUNDS 41–42
(John Wiley & Sons, Inc. 1994).

[12:720 2013]Million-Card Monte: Reforming the Markush Claim Post-AIA to
Save Synthetic Chemical Innovation

745

applicant, who seeks to benefit from the patenting process, rather than the person
skilled in art within the public who hopes to make and use the claimed subject
matter and subsequently innovate.
CONCLUSION
The foregoing argument sets forth the statutory and administrative technical
requirements that an invention must meet before an applicant is granted a patent,
and introduces the Markush claim as a mechanism by which inventors can claim
large groups of similar compounds in the alternative. 132 Though Markush claims
began as small groups of alternatives, their populations have increased
exponentially.133 Analysis of large Markush groups of chemical compounds with
innumerable alternatives under established guidelines have proven impracticable.
Markush groups implicate dire consequences for innovation, but by modifying
Markush practice, the USPTO may increase odds in favor of the next player trying to
find the Red Queen.

[M]olecular modeling in suitable computers in conjunction with appropriate
displays has become a superior substitute for the use of mechanical models in
situations where quantitative (as distinct from qualitative or semiquantitative)
information about exact molecular shapes and intra- or intermolecular
interactions is desired. . . . Molecular modeling of this type had been used quite
extensively to study the fit of enzymes with their substrates or of drug receptors
with drugs. Assuming that an X-ray structure of the enzyme is available, and
that the conformation in solution is close to that in the crystal, one can model both
the enzyme and the (small) substrate and then try to “dock” the substrate in the
active site of the enzyme. . . . The approach is useful if one tries to devise enzyme
inhibitors that must fit into the active site but should not undergo the subsequent
chemical transformations that the natural substrate will undergo. . . . If the
structure of the enzyme is not known, or in the case of a drug receptor . . . one can
actually try to model the active site or receptor if one knows the structure of a
number of substrates that interact with it . . . Then one can try to devise new
substrates (drugs) that will fit the enzyme cavity or receptor as modeled.
Id.

132 See generally 35 U.S.C. § 112 (2012); 37 C.F.R. § 1.75 (2012); MPEP, supra note 13; Ex parte
Markush, 1925 Dec. Comm’r Pat. 126 (1924).
133 Gardner & Vinter, supra note 5, at 46.

